This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

NovoSeven® is indicated for the treatment of bleeding episodes and for the prevention of bleeding in surgery or invasive procedures in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX, congenital haemophilia expected to have a high anamnestic response to factor VIII or factor IX, acquired haemophilia, congenital FVII deficiency, and Glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions or where platelets are not readily available.1

NovoSeven® is indicated for the treatment of severe postpartum haemorrhage when uterotonics are insufficient to achieve haemostasis.1,2

1.

NovoSeven® Summary of Product Characteristics. SFDA Label.

2.

Committee for Medicinal Products for Human Use (CHMP), “CHMP extension of indication variation assessment report (NovoSeven®), `EPAR’”; 22 April 2022. Procedure No. EMEA/H/C/000074/II/0116.

3.

Collins P et al. BMC Res Notes 2010;3:161.

4.

Huth-Kuhne A et al. Haematologica 2009;94(4):566–575.

5.

Kruse-Jarres R. et al. Am J Hematol 2017;92(7):695–705.

6.

Tiede A et al. Haemophilia 2019;25(6):969–978.

7.

Baudo F et al. Blood 2012;120(1):39–46.

8.

Knoebl P et al. J Thromb Haemost 2012;10(4):622–631.

9.

Delgado J et al. Br J Haematol 2003;121(1):21–35.

10.

Collins PW et al. Blood 2007;109(5):1870–1877.

11.

Baudo F, De Cataldo F. Haematologica 2004;89(1):96–100.

12.

Hay CR et al. Thromb Haemost 1997;7(8):1463–1467.

13.

Amano K et al. Haemophilia 2016;23(1):50–58.

14.

Borel-Derlon A et al. Haemophilia 2016;22 Suppl 4:3–138. Poster PO-W-4.

15.

Sumner MJ et al. Haemophilia 2007;13(5):451–461.

16.

Lentz SR et al. J Blood Med 2014;5:1–3.

17.

Sun B et al. Br J Haematol 2019. doi: 10.1111/bjh.16128. [Epub ahead of print]

18.

Türkantoz H et al. J Thromb Haemost 2019;18(1):36–43.

19.

Hedner U. Blood Rev 2015;29(S1):S4–S8.

20.

Pardos-Gea J et al. Haemophilia 2018;24(3):e163–e166.

21.

Tiede A, Worster A. Ann Hematol 2018;97(10):1889–1901.

22.

Neufeld EJ et al. Haemophilia 2018;24(4):e275-e277.

23.

Abshire T, Kenet G. Haemophilia 2008;14(5):898–902.

24.

Tiede A et al. Blood Rev 2015; 29(S1):S19–S25.

25.

Giangrande PL et al. Haemophilia 2009;15(2):501–508.

26.

Croom KF, McCormack PL. Biodrugs 2008;22(2):121–136.

27.

Rexen P et al. TH Open 2019;3:e45–e49.

28.

Pollard D et al. J Haem Pract 2017;4(1):1–5.

29.

FEIBA® Summary of Product Characteristics.

30.

Neufeld EJ et al. Blood Rev 2015;29(S1):S34–S41.

31.

Santagostino E et al. Thromb Haemost 2006;4(2):367–371.

32.

Neufeld EJ et al. Pediatr Blood Cancer 2013;60(7):1178–1183.

33.

Pruthi RK et al. Thromb Haemost 2007;98(4):726–732.

34.

Shapiro AD et al. Thromb Haemost 1998;80(5):773–778.

35.

Parameswaran R et al. Haemophilia 2005;11(2):100–106.

36.

Hemlibra® Summary of Product Characteristics.